Background and Objectives Recent data suggest increasing global prevalence of multiple sclerosis (MS). Early diagnosis of MS reduces the burden of disability-adjusted life years and associated health care costs. Yet diagnostic delays persist in MS care and even within national health care systems with robust resources, comprehensive registries, and MS subspecialist referral networks. The global prevalence and characteristics of barriers to expedited MS diagnosis, particularly in resource-restricted regions, have not been extensively studied. Recent revisions to MS diagnostic criteria demonstrate potential to facilitate earlier diagnosis, but global implementation remains largely unknown. Methods The Multiple Sclerosis International Federation third edition of the Atlas of MS was a survey that assessed the current global state of diagnosis including adoption of MS diagnostic criteria; barriers to diagnosis with respect to the patient, health care provider, and health system; and existence of national guidelines or national standards for speed of MS diagnosis. Results Coordinators from 107 countries (representing approximately 82% of the world population), participated. Eighty-three percent reported at least 1 “major barrier” to early MS diagnosis. The most frequently reported barriers included the following: “lack of awareness of MS symptoms among general public” (68%), “lack of awareness of MS symptoms among health care professionals” (59%), and “lack of availability of health care professionals with knowledge to diagnose MS” (44%). One-third reported lack of “specialist medical equipment or diagnostic tests.” Thirty-four percent reported the use of only 2017 McDonald criteria (McD-C) for diagnosis, and 79% reported 2017 McD-C as the “most commonly used criteria.” Sixty-six percent reported at least 1 barrier to the adoption of 2017 McD-C, including “neurologists lack awareness or training” by 45%. There was no significant association between national guidelines pertaining to MS diagnosis or practice standards addressing the speed of diagnosis and presence of barriers to early MS diagnosis and implementation of 2017 McD-C. Discussion This study finds pervasive consistent global barriers to early diagnosis of MS. While these barriers reflected a lack of resources in many countries, data also suggest that interventions designed to develop and implement accessible education and training can provide cost-effective opportunities to improve access to early MS diagnosis.
Background: The Atlas of MS provides a dataset on multiple sclerosis. This analysis updates the global prevalence (including separate estimates for pediatric multiple sclerosis) and incidence of multiple sclerosis, and examines changes over time using data from 2013, 2020, and 2024. Methods: Countries participating in the 2024 Atlas update confirmed or updated epidemiological data. Global prevalence was estimated using submitted case counts supplemented with pooled subregional rates and, for 2020 and 2024, literature-based imputation. Results: Experts in 133 countries representing 93% of the global population participated. Prevalence data were provided by 118 countries. Global multiple sclerosis prevalence per 100,000 rose from 24.8 (95% confidence interval: 24.73–24.80) in 2013 to 38.1 (95% confidence interval: 38.09–38.17) in 2024 and most regions showed rising prevalence; 3.1 million people now live with multiple sclerosis globally. Higher-income countries reported higher prevalence than lower-income countries. The number of reported pediatric multiple sclerosis cases increased from 7,000 in 2013 to >40,000 in 2024. Incidence data provided by 91 countries estimated that 120,000 new diagnoses occur annually. Conclusion: Global multiple sclerosis prevalence continues to rise. Strengthened and equitable data collection is essential as diagnostic criteria evolve, and these findings provide a benchmark before widespread adoption of the 2024 McDonald criteria.
Paraclinical testing incorporated within multiple sclerosis (MS) diagnostic criteria over time have facilitated earlier diagnosis, yet global implementation is largely unknown. Lack of "specialist medical equipment or diagnostic tests" was a barrier to early diagnosis of MS endorsed by a third of 107 countries surveyed in the recent Multiple Sclerosis International Federation Atlas of MS Third Edition. This study assessed global access to paraclinical testing incorporated in MS diagnostic criteria. Survey development included stakeholders with varied expertise and perspectives from all World Health Organization regions and World Bank (WB) country economy income categories. The survey assessed availability, routine use, and barriers to routine use of MRI, CSF testing, evoked potentials, optical coherence tomography, and serum aquaporin-4 immunoglobulin G and myelin oligodendrocyte glycoprotein immunoglobulin G antibody testing. Opinions regarding anticipated 2024 criteria revisions and preferences regarding the dissemination of MS guidelines were surveyed. The survey was available from April 11, 2024, to September 2, 2024. One hundred twenty-two of 149 (82%) of country coordinators participated. No paraclinical test was available across all countries. All 10 tests were available in only 41% of countries. Availability of paraclinical testing did not guarantee routine use in the diagnostic evaluation for MS. Cost and lack of expertise for performance or interpretation were frequent barriers to routine use. Such barriers were present even in WB high-income countries, but low- and low-middle-income countries reported significantly more limited availability of paraclinical testing and significantly diminished routine use to aid diagnosis of MS. This study highlights worldwide barriers and disparities in access to paraclinical testing that can expedite the diagnosis of MS. Creative approaches are urgently needed to address cost and required expertise for these paraclinical tests to improve worldwide access. Our data suggest that targeted educational efforts surrounding 2024 McDonald criteria revisions can reduce barriers to implementation. There was enthusiasm that the incorporation of these new approaches to paraclinical testing within the criteria would improve access to early MS diagnosis. This study will provide valuable baseline data to inform future assessments of global access to paraclinical testing for the diagnosis MS.
Background: To optimize the care of people with multiple sclerosis in Europe, the European Multiple Sclerosis Platform aimed to gather vital evidence from people with multiple sclerosis to understand prevalence, burden, and symptom management. Methods: An online survey was distributed by 24 European Multiple Sclerosis Platform–associated multiple sclerosis organizations across 22 countries. Descriptive statistics were applied. Results: Data from 17,151 people with multiple sclerosis revealed a mean of 13.7 symptoms. The five most prevalent symptoms included fatigue, sensory problems, sleep disturbances, cognitive impairment, and balance problems (range = 75%–93%). Respondents utilized a mean of 5.6 concurrent care modalities/strategies for symptom management, and 86% of them received disease-modifying drugs. They consulted a mean of 4.2 healthcare professionals for symptom management, with 50% experiencing coordination of care. Overall, 50% of respondents expressed satisfaction with their symptom management. However, satisfaction levels varied depending on the specific symptom: people with multiple sclerosis were twice as likely to report satisfaction with managing mobility, bladder control, and spasticity compared to managing sexual problems, fatigue, and cognitive impairment. Conclusion: This survey provides evidence of the high prevalence, burden, and impact of symptoms in people with multiple sclerosis, highlighting the need for multifaceted care strategies. The results call for a change in healthcare policies and practices.